<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20180913041032N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-12-03</date_registration>
      <primary_sponsor>Shiraz University of Medical Sciences</primary_sponsor>
      <public_title>Effect of xylitol in treatment of post-orthodontic white spot lesions</public_title>
      <acronym></acronym>
      <scientific_title>Treatment of post-orthodontic white spot lesions with 10% xylitol varnish: A randomized Clinical Trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-12-11</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>84</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/60125</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: All the participants will be randomized using dynamic randomized block design for balancing age and sex. A block randomization list will be created by https://www.sealedenvelope.com with a block size of six. The group allocation will be revealed by an assistant not directly involved in the study and a random code number will be assigned to each patient based on the randomization list created at the beginning of study, Blinding description: The participating patients, the main therapist corresponding the varnish administration and evaluate the study outcome, the person who collect and analyses data and the persons prepares the results report will be blinded with respect to the type of varnish used. In this regard the placebo varnish will be specially manufactured by the Asia ChemiTeb Co with the same basic composition and viscosity as the commercial Ariadent fluoride varnish (Asia ChemiTeb Co., Tehran, Iran). All varnishes will be stored in similar tubes and  will be labeled as A, B and C.</study_design>
      <phase>3</phase>
      <hc_freetext>White spot lesions.</hc_freetext>
      <i_freetext>Intervention 1: Intervention1: 5% fluoride varnish: Ariadent fluoride varnish (Asia ChemiTeb Co, Tehran, Iran). At the time of debonding, remaining composite material on the enamel surfaces will be removed with 12-bladed tungsten carbide bur and a low-speed hand piece followed by polishing with a rubber cup a fluoride-free pumice paste . The  varnish will be applied with a small brush in a thin layer of the facial surface of the eight anterior maxillary teeth. After 60 s of setting, the patients will be instructed not to drink within 60 min, not to eat for 4 h, and brush their teeth until the next day morning. This process will be repeated every three months (4 times during study) after cleaning and drying the teeth. Intervention 2: Intervention 2: 10% xylitol varnish. Xylitol varnish will be especially manufactured by Asia ChemiTeb Co (Tehran, Iran) with the same basic composition as the commercial Ariadent fluoride varnish (Asia ChemiTeb Co, Tehran, Iran). At the time of debonding, remaining composite material on the enamel surfaces will be removed with 12-bladed tungsten carbide bur and a low-speed hand piece followed by polishing with a rubber cup a fluoride-free pumice paste . The  varnish will be applied with a small brush in a thin layer of the facial surface of the eight anterior maxillary teeth. After 60 s of setting, the patients will be instructed not to drink within 60 min, not to eat for 4 h, and brush their teeth until the next day morning. This process will be repeated every three months (4 times during study) after cleaning and drying the teeth. Intervention 3: Control group: Placebo varnish, placebo varnish will be especially manufactured by Asia ChemiTeb Co (Tehran, Iran) with the same basic composition as the commercial Ariadent fluoride varnish (Asia ChemiTeb Co, Tehran, Iran). At the time of debonding, remaining composite material on the enamel surfaces will be removed with 12-bladed tungsten carbide bur and a low-speed hand piece followed by polishing with a rubber cup a fluoride-free pumice paste . The  varnish will be applied with a small brush in a thin layer of the facial surface of the eight anterior maxillary teeth. After 60 s of setting, the patients will be instructed not to drink within 60 min, not to eat for 4 h, and brush their teeth until the next day morning. This process will be repeated every three months (4 times during study) after cleaning and drying the teeth.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Data of primary and secondary outcomes are possible to be shared.

When:
The date of accessibility will be from the results publication.

To whom:
For whom interested

Conditions:
No specific condition needed

Where to obtain:
For receiving the documents, contact the following E-mail address: 
shavakhi.m@gmail.com

How to obtain:
The request of getting the documents should be sent through an official email. The email contents include the name and position of the person receiving the data and the reason of requesting. After evaluation by corresponding author, the documents file will be sent within 1 to 2 weeks.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Hooman Zarif Najafi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shiraz dental school, Qom abad, Ghasrodasht St.</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۱۵۸۷۸- ۷۱۹۵۶</zip>
        <telephone>+98 71 3626 3193</telephone>
        <email>zarifhooman@gmail.com</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mojgan Shavakhi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>School of dentistry, Isfahan university of medical sciences, Sofe St.</address>
        <city>اصفهان</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>81746-73461</zip>
        <telephone>+98 31 3668 0048</telephone>
        <email>shavakhi.m@gmail.com</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>The subjects will be chosen within patients aged between 14 and 25 years old who had completed fixed appliance orthodontic therapy recently.
Have at least one WSL on the facial surface of eight maxillary anterior teeth that was not presented before orthodontic treatment.</inclusion_criteria>
      <agemin>14 years</agemin>
      <agemax>25 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patient’s unwillingness to be randomly assigned to one of the three treatment groups
Ongoing medication for a chronic disease
Chronic conditions such as asthma and allergy
Any abnormal oral, medical, mental condition or neuropsychiatric disorders
Regular use of oral antiseptics
Any WSLs present on qualifying teeth with frank cavitation,
Extensive restorations on the facial surfaces of the study teeth
Dental morphologic, anatomical or developmental anomalies
Alterations of the enamel, e.g. hypoplasia, fluorosis
Chronic use of medication causing a dry mouth or known xerostomia
Known pregnancy or breastfeeding during the course of the study
Professional administration or home use of highly concentrated fluoride products not related to the study during the whole study</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>K02.61</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Dental caries on smooth surface limited to enamel</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention1: 5% fluoride varnish: Ariadent fluoride varnish (Asia ChemiTeb Co, Tehran, Iran). At the time of debonding, remaining composite material on the enamel surfaces will be removed with 12-bladed tungsten carbide bur and a low-speed hand piece followed by polishing with a rubber cup a fluoride-free pumice paste . The  varnish will be applied with a small brush in a thin layer of the facial surface of the eight anterior maxillary teeth. After 60 s of setting, the patients will be instructed not to drink within 60 min, not to eat for 4 h, and brush their teeth until the next day morning. This process will be repeated every three months (4 times during study) after cleaning and drying the teeth.</i_keyword>
      <i_keyword>Intervention 2: 10% xylitol varnish. Xylitol varnish will be especially manufactured by Asia ChemiTeb Co (Tehran, Iran) with the same basic composition as the commercial Ariadent fluoride varnish (Asia ChemiTeb Co, Tehran, Iran). At the time of debonding, remaining composite material on the enamel surfaces will be removed with 12-bladed tungsten carbide bur and a low-speed hand piece followed by polishing with a rubber cup a fluoride-free pumice paste . The  varnish will be applied with a small brush in a thin layer of the facial surface of the eight anterior maxillary teeth. After 60 s of setting, the patients will be instructed not to drink within 60 min, not to eat for 4 h, and brush their teeth until the next day morning. This process will be repeated every three months (4 times during study) after cleaning and drying the teeth.</i_keyword>
      <i_keyword>Control group: Placebo varnish, placebo varnish will be especially manufactured by Asia ChemiTeb Co (Tehran, Iran) with the same basic composition as the commercial Ariadent fluoride varnish (Asia ChemiTeb Co, Tehran, Iran). At the time of debonding, remaining composite material on the enamel surfaces will be removed with 12-bladed tungsten carbide bur and a low-speed hand piece followed by polishing with a rubber cup a fluoride-free pumice paste . The  varnish will be applied with a small brush in a thin layer of the facial surface of the eight anterior maxillary teeth. After 60 s of setting, the patients will be instructed not to drink within 60 min, not to eat for 4 h, and brush their teeth until the next day morning. This process will be repeated every three months (4 times during study) after cleaning and drying the teeth.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Enamel mineral content. Timepoint: Baseline, 6 and 12 month post orthodontic treatment. Method of measurement: DIAGNOdent pen.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Visual assessment of white spot lesions. Timepoint: baseline and 12 month post orthodontic treatment. Method of measurement: The labial surface of maxillary incisors, cuspids and premolars will be assessed according to Gorlick et al. score 1: no white spot lesion, score 2: slight white spot lesion (thin rim). score 3:  excessive white spot lesion (thick band), and score 4: white spot lesion with cavitation.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shiraz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-07-14</approval_date>
        <contact_name>Research Ethics Committees of School of Dentistry- Shiraz University of Medical Sciences</contact_name>
        <contact_address>School of Dentistry, Qom Abad, Ghasrodasht St Shiraz Fars Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
